FIGURE 5: The process of generating Cdc13-independent survivors (cdc13Δ-cells) comprises a reversible component.

(A) Schematic representation of the procedure used to generate S2 survivors and second generation cdc13Δ-A2 of Cdc13-independent survivors. S1 survivors and cdc13Δ-A1 were generated as described in Fig. 1. S2 survivor cells were derived from cdc13Δ-A1. These cells were grown for up to 220 generations (220G) after transformation with the plasmid carrying the cdc13-1 allele. For cdc13Δ-A2 cells (MLY123), the loss of the pCDC13 plasmid was verified by growing cells on FOA synthetic medium.

(B) Cells identified with symbols as in (A) were spotted onto YEPD plates with or without hydroxyurea (HU) and incubated for 72 h at 23°C. A haploid rad52Δ strain was used as control for HU sensitivity.

(C) Rate of successful cdc13-independent cell formation (calculated by fluctuation test) for survivors S1 (MLY112) and survivors S2 (MLY122 + pcdc13-1). S2 survivors were grown for 50 or 220 generations after pcdc13-1 introduction and before the fluctuation test for plasmid loss was performed.

(D) Western blot of whole cell protein extracts prepared from strains indicated with the same symbols as in (A)(top). Cell treatment with bleomycin is indicated with – and +, and the blot was probed with an anti-Rad52 antibody as in Fig. 1.

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this. Please refer to our "privacy statement" and our "terms of use" for further information.